Compounded Versions Of Weight Loss And Diabetes Drugs Led To Death And Hospitalization, Novo Nordisk Says It Is Aware

Earlier, Novo Nordisk A/S (NYSE:NVO) petitioned the FDA to ban compounding pharmacies from producing cheaper, unapproved versions of its drugs Wegovy and Ozempic.

Amid shortages and rising demand for branded drugs, compounded semaglutide has gained popularity due to its affordability.

However, Novo Nordisk contends that only FDA-approved versions should be available, emphasizing the safety risks associated with compounded drugs.

Novo Nordisk’s Chief Financial Officer Karsten Munk Knudsen has reportedly confirmed that the company was aware of at least ten deaths and 100 hospitalizations linked to these compounded versions of semaglutide-based drugs.

Also Read: Eli Lilly Sues Some Vendors For Unauthorized Sale Of Fake Weight-Loss Drug

However, he noted that no definitive cause of death is identified in the reports, as the data is pulled from the FDA adverse events database.

Last ...